Pharmaxis has conducted a number of clinical trials as part of the regulatory approvals process for Bronchitol.
Cystic Fibrosis (cont’d)
|Description||CF202: Dosing Study|
|Sites||Argentina , Canada|
|Description||CF201: Proof of concept - ability to improve FEV1 and quality of life|
No further clinical development is planned for bronchiectasis.
|Description||B305: Long term administration of Bronchitol|
|Sites||Australia, EU, LA, New Zealand, US|
* ClinicalTrials.gov is a service provided by the U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine. ClinicalTrials.gov provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions. Pharmaxis chooses to publish all Pivotal Trials on the ClinicalTrials.gov website.
*** No further clinical development planned in Bronchiectasis